[1. Ayres TC, Bond JW. A chemical analysis examining the pharmacology of novel psychoactive substances freely available over the internet and their impact on public (ill) health. Legal highs or illegal highs? BMJ Open 2012;2:e000977.10.1136/bmjopen-2012-000977]Search in Google Scholar
[2. European Monitoring Centre for Drugs and Drugs Addiction. Annual report 2010: the state of the drugs problem in Europe. Luxembourg: Publications Office of the European Union; 2010. http://www.emcdda.europa.eu/publications/annual-report/2010 (20.05.2019).]Search in Google Scholar
[3. Schifano F, Albanese A, Fergus S, Stair JL, Deluca P, Corazza O, et al. Mephe-drone (4-methylmethcathinone; ‘meow meow’): chemical, pharmacological and clinical issues. Psychopharmacology (Berl) 2011;214(3):593-602.10.1007/s00213-010-2070-x]Search in Google Scholar
[4. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu LH, Huwyler J, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013;168(2):458-70.10.1111/j.1476-5381.2012.02145.x]Search in Google Scholar
[5. Blanckaert P, van Amsterdam J, Brunt T, van den Berg J, Van Durme F, Maudens K, et al. 4-Methyl-amphetamine: a health threat for recreational amphetamine users. J Psychopharmacol 2013;27(9):817-22.10.1177/0269881113487950]Search in Google Scholar
[6. Miliano C, Serpelloni G, Rimondo C, Mereu M, Marti M, De Luca MA. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties and cannabimimetics and amphetamine-like stimulants. Front Neurosci 2016;10:153.10.3389/fnins.2016.00153]Search in Google Scholar
[7. Miller KJ, Anderholm DC, Ames MM. Metabolic activation of serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem Pharmacol 1986;35(10):1737-42.10.1016/0006-2952(86)90332-1]Search in Google Scholar
[8. Wojcieszak J. Związki psychostymulujące. In: Zawilska JB, Andrzejczak D, Wojcieszak W. „Dopalacze” i leki OTC – nowi gracze na scenie związków psychoaktywnych. Łódź: Uniwersytet Medyczny w Łodzi; 2016. p. 45-71.]Search in Google Scholar
[9. Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii. Dz. U. Nr 179, poz. 1485.]Search in Google Scholar
[10. Antonowicz JL, Metzger AK, Ramanujam SL. Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases. Gen Hosp Psychiatry 2011;33(6):640.e5-6.10.1016/j.genhosppsych.2011.04.01021749840]Search in Google Scholar
[11. Fullajtar M, Ferencz C. Designer drug induced psychosis. Neuropsychopharmacol Hung 2012;14(2):137-40.]Search in Google Scholar
[12. Mugele J, Nañagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann Emerg Med 2012;60(1):100-2.10.1016/j.annemergmed.2011.11.03322237165]Search in Google Scholar
[13. Kelly JP. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test Anal 2011;3(7-8):439-53.10.1002/dta.31321755607]Search in Google Scholar
[14. Zawilska JB, Słomiak K, Wasiak M, Woźniak P, Massalski M, Krupa E, et. al. β-cathinones derivatives – a new generation of dangerous psychostimulant “designer drug”. Prz Lek 2013;70(6):386-91.]Search in Google Scholar
[15. Vevelstad M, Øiestad EL, Bremer S, Bogen IL, Zackrisson AL, Arnestad M. Is toxicity of PMMA (paramethoxymethamphetamine) associated with cytochrome P450 pharmacogenetics? Forensic Sci Int 2016;261:137-47.]Search in Google Scholar